The Bear Cloud Cirrus Pillows Help Me Sleep at Night, and They're 30% Off This Summer
The pillows you use every night can have a huge impact on your quality of sleep. As a self-proclaimed poor sleeper (with the data to prove it), I've tried a ton of sleep products and accessories over the years to help me get better rest, including pillows.
As a combination sleeper, I switch positions constantly throughout the night, making it hard to find a pillow that's comfortable regardless of how weirdly I contort my body while sleeping. A few months ago, I swapped out our pillows (again) to try Bear's Cloud Cirrus Pillows and haven't looked back.
I love sleeping on Bear's fluffy Cloud Cirrus Pillows.
Aly Lopez/CNET
These pillows are incredibly fluffy and light. As soon as I rest my head on them, I feel like I'm floating away on a soft cloud. The material used inside is a 3D polyester fill, which is breathable and hypoallergenic -- a great feature for those with allergen sensitivities. I've also found that I sleep cooler on the Cloud Cirrus Pillows than others I've tried due to their light construction that allows for more airflow. To top it all off, they're also made cruelty-free thanks to the down-alternative materials.
Despite being soft and fluffy, they still offer plenty of support and help keep my neck and spine aligned no matter which position I'm sleeping in.
Bear offers free shipping, a lifetime warranty for mattresses and a 30-night return period for sleep accessories (including pillows) -- although with the cloudlike experience you'll have on the Bear Cloud Cirrus Pillows, I doubt you'll want to return them.
For more options, check out our roundup of the best pillow for every kind of sleeper.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease
– The pivotal Phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualized exacerbation rate (AER) at 52 weeks when astegolimab was given every two weeks – – The Phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks – – The safety profile of astegolimab was consistent with previously reported data, with no new safety signals identified – – Analysis of the ALIENTO and ARNASA data will be discussed with regulatory authorities and shared at an upcoming medical meeting – SOUTH SAN FRANCISCO, Calif., July 21, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase IIb ALIENTO (n=1,301) and the Phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations. The pivotal Phase IIb ALIENTO study met its primary endpoint and showed that astegolimab reduced the annualized exacerbation rate (AER) by a statistically significant 15.4% at 52 weeks, when given every two weeks. However, the Phase III ARNASA study did not meet its primary endpoint of a statistically significant reduction in the AER, demonstrating a numerical 14.5% reduction at 52 weeks when astegolimab was given every two weeks. The results were generally consistent across secondary endpoints in both studies. The total number of exacerbations was lower than prospectively anticipated in both trials. The safety profile of astegolimab was consistent with previously reported data, with no new safety signals identified. "While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for managing this debilitating and complex disease," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "This was the first set of studies in an 'all-comers' COPD population, and we will discuss these data with regulatory authorities to evaluate next steps for astegolimab." Detailed results from ALIENTO and ARNASA will be shared at an upcoming medical meeting. About the ALIENTO and ARNASA studies Astegolimab is an investigational, fully human anti-ST2 monoclonal antibody designed to bind with high affinity to the ST2 receptor, thereby blocking the signaling of IL-33. The astegolimab COPD pivotal program consists of two registrational studies, the Phase IIb ALIENTO (NCT05037929) and Phase III ARNASA (NCT05595642) studies. Both ALIENTO and ARNASA are double-blinded, placebo-controlled, multi-center studies that evaluate the efficacy and safety of astegolimab administered every two or every four weeks in patients with COPD on top of standard of care maintenance therapy. Patients in the studies included former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations. The primary analysis is based on the initial phase of the study, which consisted of 1,301 patients for ALIENTO and 1,375 patients for ARNASA. The primary endpoint is the reduction in the annualized rate of moderate and severe COPD exacerbations (AER) over the 52-week treatment period. AER is the total number of exacerbations (a sudden worsening in airway function and respiratory symptoms) occurring over the relevant treatment period, divided by the total number of patient years. Standard of care maintenance therapy for both studies was one of the following combinations - inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA); long-acting muscarinic antagonist (LAMA) plus LABA; ICS plus LAMA plus LABA. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit View source version on Contacts Media Contact:Lindsey Mathias, (650) 467-6800 Advocacy Contact:Del Conyers, (571) 684-1616 Investor Contacts:Loren Kalm, (650) 225-3217Bruno Eschli, +41 61 68-75284 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
"I thought I might be dead in a few months" - Kareem Abdul-Jabbar on getting diagnosed with leukemia
"I thought I might be dead in a few months" - Kareem Abdul-Jabbar on getting diagnosed with leukemia originally appeared on Basketball Network. Kareem Abdul-Jabbar, born in 1947, is nearing 80. Despite that advanced age, he still seems to be going strong. Basketball fans should appreciate that, not just for his longevity, but because one story about the sports icon shows how quickly it can all end. In 2011, the Hall of Famer shared his reaction to a leukemia diagnosis — news that hit like a thunderbolt. Fearing the worst In November 2009, Abdul-Jabbar revealed he was diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia, a blood and bone marrow cancer. The two-time Finals MVP said he had received the devastating news in December 2008. While shocking on its own, it hit harder because of memories of his close friend Bruno Kirby. The actor, known for "When Harry Met Sally…" and "Good Morning, Vietnam," died from leukemia complications in August 2006, "within 30 days" of his diagnosis, Kareem recalled. Of course, every case is different, and disease progression varies. Still, the Los Angeles Lakers legend admitted he instantly feared the worst when he received the same diagnosis, mainly because he "really had no understanding" of what he was dealing with. "I thought I might be dead in a few months," said Abul-Jabbar, per battle Fast forward to 2011, Kareem took to X (formerly Twitter) with hopeful news: he was cancer-free — a statement he later corrected. "You're never really cancer-free and I should have known that," he said. "My cancer right now is at an absolute minimum… It's not life-threatening at this point in my life." Following a similar approach to former superstar teammate Magic Johnson's powerful handling of his HIV diagnosis, Abdul-Jabbar faced his own illness head-on. For instance, the New York native became a spokesperson for Novartis, makers of Gleevec, the drug that transforms chronic myeloid leukemia into a manageable condition and boosts survival rates. "Medical science has made great strides over the last 20 years," Kareem noted. "People in my position are able to live their lives to the fullest. I'm very grateful for that. I'm lucky that they caught it in enough time, and I've responded well to the medication. If not for the success that medicine has made, I might be part of a much different story right now." It wasn't the only time cancer challenged him. In 2020, Abdul-Jabbar revealed he'd been diagnosed with prostate cancer eleven years earlier. And while he fought it again, the now 78-year-old didn't forget those in the same fight. Kareem acknowledged that as an NBA star, he had access to top-tier medical care — something many in the Black community lack. "While I'm grateful for my advantages, I'm acutely aware that many others in the Black community do not have the same options and that is my responsibility to join with those fighting to change that," he wrote, per Good Morning America. "Because Black lives are at risk. Serious risk." Abdul-Jabbar was always the vocal leader in the Showtime Lakers locker room — a voice he clearly hasn't lost, even with adversity testing him time and story was originally reported by Basketball Network on Jul 20, 2025, where it first appeared.
Yahoo
an hour ago
- Yahoo
The Wholesome Company Launches Rē•prev, a Calming Drink Mix for Anxiousness Support
Grapevine, TX, July 21, 2025 (GLOBE NEWSWIRE) -- The Wholesome Company, a wellness brand focused on holistic and evidence-aligned support for mental well-being, is pleased to announce the launch of Rē•prev, a breakthrough nutritional supplement formulated to help individuals reduce anxiousness, manage stress, and improve sleep quality. Designed for rapid absorption and daily use, Rē•prev combines naturally calming ingredients with a flexible, easy-to-use format aimed at supporting emotional resilience in today's high-stress landscape. Rē•prev Drink Mix According to the National Comorbidity Study Replication, anxiety has become one of the most pressing public health concerns of the decade, affecting over 40 million adults in the US. These numbers have given rise to a growing number of individuals seeking accessible, non-habit-forming tools to help them regain a sense of calm and control. Rē•prev addresses this need through naturally calming ingredients and a multi-system approach to relaxation and emotional balance. Its key ingredients, L-Theanine, GABA, Magnesium, and Tart Cherry Powder, are known for their calming and sleep-supportive properties, working together to ease tension, promote relaxation, and enhance restorative sleep without sedation. 'Many people today are looking for tools that help them stay calm, focused, and emotionally grounded without turning to long-term prescription medication or habit-forming substances,' said Charles Schwanky, a representative for The Wholesome Company. 'Rē•prev was created to meet this need, offering a natural, fast-acting option to help users regain control in moments of stress.' A Multi-Pathway Approach to Stress Relief Rather than relying on a single mechanism of action, Rē•prev was intentionally developed to target three interconnected physiological systems – neurotransmitters, hormones, and sleep cycles – that govern how the body perceives, processes, and recovers from stress. This integrated approach reflects the complex nature of stress and aims to provide a more balanced, sustainable relief across both short and long-term needs. Neurotransmitters: Ingredients such as L-Theanine and GABA support the activity of brain chemicals like serotonin, dopamine, and GABA itself, which are central to mood regulation and relaxation. Hormones: The formula also considers the impact of cortisol, the body's primary stress hormone, by supporting pathways that naturally help reduce its effects. Sleep cycles: Rē•prev includes compounds that interact with melatonin production and brainwave modulation to support healthy sleep rhythms, a critical component in long-term mental well-being. This multi-pathway approach allows Rē•prev to work with the body's natural systems, offering fast-acting support during acute stress while also promoting long-term emotional balance through consistent, daily use. Formulated for Rapid Absorption and Everyday Flexibility Rē•prev comes in convenient stick packs designed to mix easily with water or a preferred beverage. According to the brand, its rapid-absorption formula allows calming effects to be felt within 30 to 60 minutes of consumption. Depending on individual needs, users can take one to three servings per day. Each dose is carefully calibrated to provide flexibility based on the level of stress or anxiety being experienced. One stick pack may be used for light daily stress or general calm. Two stick packs may be suitable for moderate anxiety or busy days. Three stick packs can be taken in particularly high-stress moments or when deeper relaxation is needed. The drink mix is available in three naturally flavored varieties: Berry Bliss, Lavender Breeze, and Orange Dreamsicle. Rē•prev Flavors Responding to a Growing Need Rē•prev's launch reflects a recent shift in how individuals approach mental wellness. As reports of chronic stress, sleep disruption, restlessness, and emotional burnout increase, more people are actively seeking tools that help them stay grounded, present, and calm. The Wholesome Company aims to offer Rē•prev as an accessible solution that can fit within one's everyday wellness routine. 'If you've ever suffered from severe anxiousness or stress-induced panic, then you know what it's like to feel like you're all alone without any lifeline to help you, and that can be extremely debilitating,' said J. Roy, Co-Founder & CEO of The Wholesome Company. 'After years of personally struggling with extreme anxiousness, I finally found a balance of ingredients that took me out of fight-or-flight and gave me the lifeline I had been desperately seeking. I couldn't keep it to myself, knowing what it had done for my own life, hence the birth of Rē•prev. Our hope is that Rē•prev becomes the rescuer in your pocket that it has been for so many of us here at The Wholesome Co.' Availability Rē•prev is now available through The Wholesome Company website at Each box contains 30 single-serving stick packs and can be ordered in individual flavors or as part of a variety pack. About The Wholesome Company The Wholesome Company is a wellness brand based in Texas, focused on developing science-informed, naturally formulated solutions that support mental and emotional well-being. Committed to transparency, clean ingredients, and real-world usability, the company creates products that fit seamlessly into daily life. The Wholesome Company empowers individuals with approachable, thoughtfully crafted tools that support balance, resilience, and overall peace of mind. Media Contact Company Name: The Wholesome CompanyContact Person: Charles SchwankyContact Number: (800) 935-6561Email: hello@ United StatesWebsite: Media Handles: @wholesomereprev Disclaimer: The statements made regarding these products have not been evaluated by the Food and Drug Administration. This press release is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please check with your doctor. The news site hosting this press release is not associated with (Company Name). It is merely publishing a press release announcement submitted by a company, without any stated or implied endorsement of the product or service. CONTACT: Media Contact Company Name: The Wholesome Company Contact Person: Charles Schwanky Contact Number: (800) 935-6561 Email: hello@ Country: United States Website: Social Media Handles: @wholesomereprevError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
